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Background: Though adiponectin has been associated with insulin resistance and cardiovascular risk factors, the 
relationship between adiponectin and polycystic ovary syndrome (PCOS) remains controversial. The aim of this study 
was to compare adiponectin level in women with PCOS and without PCOS, and to investigate the relationship between 
adiponectin level and metabolic variables including insulin resistance.
Methods: 60 women with PCOS were enrolled along with a control group of 80 healthy women, matched for age and body 
mass index (BMI). We measured hormonal and metabolic parameters, as well as the plasma adiponectin concentration 
of each participant. We estimated the insulin sensitivity according to the quantitative insulin sensitivity check index 
(QUICKI). 
Results: The PCOS group displayed significantly lower level of adiponectin (P < 0.001) after adjustment for age, BMI, mean 
blood pressure, fasting glucose, fasting insulin, and several metabolic parameters. Adiponectin levels were positively 
correlated with QUICKI in the PCOS group (P < 0.001) and the control group (P = 0.03). Following step-wise multiple 
regression analysis, however, adiponectin level was positively correlated with QUICKI in the control group only (P = 0.03). 
In addition, adiponectin level was found to be independently associated with HDL-cholesterol level (P < 0.001) and BMI (P 
= 0.02) in the PCOS group and independently associated with HDL-cholesterol (P = 0.02) in the control group.
Conclusion: We report decreased adiponectin level in PCOS patients in relation to controls independently of insulin 
resistance or other metabolic factors. And adiponectin is associated with both lipid metabolism and obesity, which, 
in turn, is related to insulin resistance in PCOS. Further studies are needed to clarify the mechanism of adiponectin in 
PCOS.
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INTRODUCTION
Polycystic ovary syndrome (PCOS) is a common endocrine 
disorder
1) among women of child-bearing age. It is characterized 
by chronic anovulation (oligomenorrhea or amenorrhea) 
hyperandrogenemia, hirsutism and acne. Recently, many studies 
have focused on the metabolic disorders in PCOS
2,3) that lead 
to cardiovascular events, dyslipidemia, insulin resistance,
4,5) and 
metabolic dysfunction is widely regarded as the leading cause of 
the syndrome. 
Adiponectin is a cytokine produced and secreted exclusively 
from adipose tissue. It is believed to serve an anti-in￿ammatory 
role, as well as have anti-atherogenic and cardioprotective pro-Hyun-Young Shin, et al: Adiponectin in Women with Polycystic Ovary Syndrome 
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within the first 10 days of menstruation. In PCOS patients 
with severe oligomenorrhea or amenorrhea, we studied in 
randomized period. We had collected venous blood samples 
in the morning from 8 AM to 10 AM after overnight fasting in 
each subject. We measured the plasma concentration of LH, 
FSH, estradiol (E2), total testosterone, fasting insulin levels by 
electrochemiluminescence immunoassay (Roche, Indianapolis, 
IN, USA) and sex-hormone binding globulin (SHBG) level by an 
Immulite 2000 analyser (Diagnostic Product Co., Los Angeles, 
CA, USA). Fasting glucose, total cholesterol, triglyceride (TG), 
high-density lipoprotein (HDL)-cholesterol levels were measured 
using an ADVIA 1650 chemistry system (Bayer, Terrytown, NY, 
USA), and low-density lipoprotein (LDL)-cholesterol levels 
were calculated using the Friedewald equation, for serum TG 
levels below 400 mg/dL. De￿nition of clinical hyperandrogenism 
was presence of acne, hirsutism (Ferriman–Gallwey score ≥ 
8) or alopecia. The quantitative insulin sensitivity check index 
(QUICKI)
21) as meaning of insulin sensitivity was calculated as 
follow: 1 / [log (fasting insulin) + log (fasting glucose)]. Plasma 
adiponectin levels were measured by an enzyme immunoassay 
kit (AdipoGen, Seoul, Korea) and the inter- and intra-assay 
variability were 4.63% ± 0.82% and 2.72% ± 0.52%, respectively.
3. Statistical Analysis 
We analyzed all of the data using the SAS 9.1 (SAS Inst., 
Cary, NC, USA) statistical program and expressed the data as 
mean ± SD or median with interquartile range (IQR, 25th-
75th percentile). Comparisons of the PCOS to the control group 
employed either the Student’s t-test or the Wilcoxon rank sum 
test. Adiponectin levels of the PCOS and the control groups were 
compared using an analysis of covariance (ANCOVA) adjusted 
for age, BMI, mean blood pressure, fasting glucose, fasting insulin, 
TG, HDL-cholesterol, LDL-cholesterol, E2, LH/FSH, total 
testosterone and SHGB levels. Pearson’s correlation coe￿cients 
were used for assessing the correlation between adiponectin levels 
and metabolic variables. Multivariate regression analysis was used 
for clari￿cation of independent associations between adiponectin 
levels and other metabolic parameters. 
perties
6) and an insulin-sensitizing effect.
7,8) In addition, adipo-
nectin levels are known to have an inverse relationship with 
insulin resistance in obesity, type 2 diabetes, dyslipidemia, 
hypertension and cardiovascular disease. In PCOS, however, 
the association between adiponectin levels and PCOS remains 
controversial
9-18) and it is unclear so far whether adiponectin is a 
primary defect or occurred secondary to or in parallel with this 
insulin resistance.
11-14,17) 
The aim of this study was to compare adiponectin levels in 
women with PCOS to those of healthy women, and to investigate 
the independent relationship between plasma adiponectin 
concentrations and metabolic variables including insulin 
resistance. 
METHODS
1. Subjects
We included 60 women patients with PCOS and a control 
group of 80 healthy women, matched for age and BMI. PCOS 
subjects were enrolled when they had satisfied two of the three 
following criteria: oligomenorrhea or amenorrhea, clinical or 
biochemical hyperandrogenism, and ultrasonographic polycystic 
ovarian morphology.
19) We excluded the subjects who had weight-
related amenorrhea, Cushing’s syndrome, late-onset congenital 
adrenal hyperplasia, thyroid dysfunction, hyperprolactinaemia 
and androgen secreting tumours.
20) Additional exclusionary 
criteria were diabetes, hypertension, chronic renal disease, 
overt proteinuria, smoking, alcohol use, and medication usage, 
including oral contraceptives. All of the control subjects had 
normal, regular menstruation, normal ovarian findings on 
ultrasound, and normal luteinizing hormone (LH) and follicle-
stimulating hormone (FSH) levels. None displayed hirsutism. All 
of the test subjects provided written informed consent bearing 
their signatures, and the study procedure was approved by the 
Institutional Review Board of Severance Hospital. 
2. Methods
Anthropometric measurements were performed with sub-
jects wearing light clothing without shoes. BMI was calculated 
by dividing weight by square of height (kg/m
2). Subjects with 
mild oligomenorrhea and healthy control subjects visited Hyun-Young Shin, et al: Adiponectin in Women with Polycystic Ovary Syndrome
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TG, HDL-cholesterol, LDL-cholesterol, E2, LH/FSH, total 
testosterone and SHBG levels using ANCOVA, the PCOS group 
had signi￿cantly lower level of adiponectin (PCOS, 6.99 ± 0.50 
ug/mL; Control, 10.79 ± 0.71 ug/mL; P < 0.001) (Figure 1). 
Adiponetin level was significantly negatively correlated 
with BMI, systolic blood pressure, diastolic blood pressure, TG, 
fasting insulin, testosterone and positively correlated with HDL-
cholesterol in the PCOS group (Table 2). QUICKI had positive 
association with adiponectin level in the PCOS group and the 
control group (P < 0.001; P = 0.03, respectively). However, 
after step-wise multiple regression analysis, adiponectin level 
was positively correlated with QUICKI in the control group 
only (P = 0.03). In addition, adiponectin level was found to be 
independently associated with HDL-cholesterol level (P < 0.001) 
and BMI (P = 0.02) in the PCOS group and independently 
associated with HDL-cholesterol level (P = 0.02) in the control 
group, as shown in Table 3. 
DISCUSSION 
PCOS is a complex hormonal and metabolic syndrome, 
com prising hyperandrogenemia, reproductive abnormalities, 
glucose intolerance, atherogenic lipid pro￿le, obesity and insulin 
RESULTS
￿e characteristics of the PCOS and the control groups are 
summarized in Table 1. Diastolic blood pressure, fasting glucose, 
TG, fasting insulin and CRP levels were all significantly higher 
in the PCOS group, while QUICKI, E2 and SHBG levels were 
significantly lower in the PCOS group. After adjustment for 
age, BMI, mean blood pressure, fasting glucose, fasting insulin, 
Table 1. Baseline characteristics of women with PCOS and the 
control groups.
Characteristics PCOS (n = 60) Control (n = 80) P-value
Age (y) 29.0 ± 3.9 30.5 ± 5.4 0.06
BMI (kg/m
2) 25.1 ± 5.5 25.0 ± 3.3 0.86
Systolic BP (mm Hg)      116.9 ± 12.8       117.8 ± 9.6 0.65
Diastolic BP 
  (mm Hg) 
76.2 ± 10.5 71.2 ± 7.1   0.001
Fasting glucose
 (mg/dL)
94.0 ± 14.8 89.6 ± 8.9 0.03
Total cholesterol  
  (mg/dL)
175.4 ± 30.7 174.4 ± 28.5 0.85
Triglyceride
  (mg/dL)
95.0 (64.3-146.0) 69.5 (52.8-92.8)   0.001
HDL-cholesterol 
  (mg/dL)
58.5 ± 18.4   57.4 ± 11.2 0.67
Fasting insulin
  (μIU/mL)
8.30 (3.90-15.72) 5.66 (3.70-7.78)   0.006
QUICKI 0.156 ± 0.025   0.163 ± 0.015 0.03
LH/FSH 1.76 ± 1.49   1.70 ± 1.16 0.83
E2 (pmol/L) 32.4 (24.1-43.1) 77.2 (57.6-184.1) <0.001
Testosterone
  (nmol/L)
0.49 ± 0.23 0.48 ± 0.3 0.96
SHBG (nmol/L) 46.4 ± 33.0   53.8 ± 21.1 <0.001
CRP (mg/dL) 0.30 (0.09-0.62) 0.12 (0.07-0.49) 0.03
Values are presented as mean ± SD or median with IQR (25th-75th 
percentile). P-values were calculated by the Student's t-test or 
Wilcoxon’s rank sum test.
PCOS: polycystic ovary syndrome, BMI: body mass index, BP: 
blood pressure, HDL: high-density lipoprotein, QUICKI: quantative 
insulin sensitivity check index, LH: luteinizing hormone, FSH: 
follicle-stimulating hormone, E2: estradiol, SHBG: sex-hormone 
binding globulin, CRP: C-reactive protein.
Figure 1. Adiponectin levels in women with the polycystic ovary 
syndrome (PCOS) and control groups (6.99 ± 0.50 ug/mL, 10.79 
± 0.71 ug/mL, P < 0.001, respectively). *P-value (<0.001) was 
calculated using ANCOVA adjusted for age, body mass index, mean 
blood pressure, fasting glucose, fasting insulin, triglyceride, high-
density lipoprotein cholesterol, low-density lipoprotein cholesterol, 
estradiol, lute  inizing hormone/follicle-stimulating hormone, total 
testo  sterone and sex-hormone binding globulin levels.Hyun-Young Shin, et al: Adiponectin in Women with Polycystic Ovary Syndrome 
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resistance.
22-24) ￿e pathogenesis is not clear, but it is conceivably 
due to immature ovarian cysts and dysregulation of insulin 
signaling in theca cells resulting from genetic defects, extrinsic 
exposures, or both.
25) Adiponectin, a 247 amino acid polypeptide, 
secreted predominantly from adipose tissues, is inversely related 
with obesity, metabolic syndrome and insulin resistance.
7,8,20,26,27) 
￿e metabolic mechanism of adiponectin is not fully understood, 
but regulation of glucose and lipid metabolism via stimulation 
of fatty acid oxidation, suppression of hepatic glucose output 
and increased insulin sensitivity in liver and skeletal muscles are 
known to be key roles of adiponectin.
28,29) 
In previous studies addressing the topic, the relationship 
between adiponectin and PCOS has been controversial, though 
a large proportion of such studies
9-13) have shown that low 
adiponectin levels were found in the PCOS group when com-
pared to the control group. And it is unclear so far whether 
adipo nectin is a primary defect or occurred secondary to or in 
parallel with this insulin resistance.
11-14,17) In our study, the PCOS 
group had significantly lower adiponectin when compared to 
the non-PCOS group independently of insulin resistance or 
other metabolic factors. In addition, we found adiponectin 
correlated with insulin levels and QUICKI in both PCOS pa-
tients and control subjects, therefore, the association between 
adiponectin and insulin resistance indices does not represent a 
typical ￿nding of PCOS status. Besides, our multivariate model 
shows that independent association between adiponectin and 
QUICKI was found only in the control group not in the PCOS 
group. ￿is implies an alternative explanation other than insulin 
resistance should be needed with respect to those relationship. 
An additional intriguing finding from our study is the fact that 
serum lipid profiles and BMI were independently correlated 
with adiponectin level in the PCOS group. Because regulation 
of fatty acid metabolism and obesity is closely associated with 
insulin resistance,
30) adiponectin might affect insulin resistance 
and metabolic abnormalities in PCOS through dysregulated lipid 
metabolism and obesity, although the exact pathway is unclear. 
The salient limitation of our study was that we did not 
Table 3. Step-wise multiple linear regression analysis to identify 
clinical variables associated with adiponectin level as a dependant 
variable.
Variables Model R
2 SE F P-value
PCOS
HDL-cholesterol  0.29 0.02    30.04 <0.001
BMI  0.34 0.08 6.06 0.02
Control
HDL-cholesterol 0.13 0.05 6.30 0.02
Fasting glucose 0.20 0.20 4.23 0.05
QUICKI 0.29    45.63 5.17 0.03
SHBG 0.34 0.03 2.92 0.10
CRP 0.38 0.44 2.84 0.10
LH 0.42 0.08 2.61 0.11
P-values of all models were calculated by the multiple regression 
analysis adjusted for age and BMI. 
PCOS: polycystic ovary syndrome, HDL: high-density lipoprotein, 
BMI: body mass index, QUICKI: quantative insulin sensitivity 
check index, SHBG: sex-hormone binding globulin, CRP: 
C-reactive protein, LH: luteinizing hormone.
Table 2. Correlation of adiponectin level and metabolic factors in 
women with the PCOS and the control groups.
PCOS (n = 60) Control (n = 80)
r P-value r P-value
Age (y) -0.04 0.73 -0.13 0.34
BMI (kg/m
2) -0.46 <0.001 -0.23 0.08
Systolic BP (mm Hg) -0.29    0.009  -0.08 0.55
Diastolic BP (mm Hg) -0.30    0.006 -0.08 0.58
Fasting glucose (mg/dL) -0.18 0.12 0.07 0.59
Total cholesterol (mg/dL)     0.11 0.34 0.13 0.34
Triglyceride (mg/dL) -0.28 0.01 -0.27 0.04
HDL-cholesterol (mg/dL)     0.55 <0.001 0.42 <0.001
Fasting insulin (μIU/mL) -0.40 <0.001 -0.28 0.03
QUICKI     0.41 <0.001 0.29 0.03
LH/FSH     0.20 0.15 -0.002 0.99
E2 (pmol/L)     0.01 0.94 0.16 0.25
Testosterone (nmol/L) -0.10 0.04 0.06 0.66
SHBG (nmol/L)     0.31   0.006 0.08 0.57
Coefficients (r) and P-values were calculated using the Pearson's 
correlation model.
PCOS: polycystic ovary syndrome, BMI: body mass index, BP: 
blood pressure, HDL: high-density lipoprotein, QUICKI: quantative 
insulin sensitivity check index, LH: luteinizing hormone, FSH: 
follicle-stimulating hormone, E2: estradiol, SHBG: sex-hormone 
binding globulin.Hyun-Young Shin, et al: Adiponectin in Women with Polycystic Ovary Syndrome
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adolescents. Curr Opin Endocrinol Diabetes Obes 2008;15: 
30-6.  
6. Krentz AJ, von Muhlen D, Barrett-Connor E. Adipocy-
tokines, sex hormones, and cardiovascular risk factors in 
postmenopausal women: factor analysis of the Rancho 
Bernardo study. Horm Metab Res 2009;41:773-7.  
7. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, 
Hansen BC, et al. Circulating concentrations of the adipocyte 
protein adiponectin are decreased in parallel with reduced 
insulin sensitivity during the progression to type 2 diabetes in 
rhesus monkeys. Diabetes 2001;50:1126-33.  
8. Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand 
F, Rahe S, et al. Plasma adiponectin concentrations predict 
insulin sensitivity of both glucose and lipid metabolism. 
Diabetes 2003;52:239-43.  
9. Sepilian V, Nagamani M. Adiponectin levels in women with 
polycystic ovary syndrome and severe insulin resistance. J Soc 
Gynecol Investig 2005;12:129-34.  
10. Wickham EP 3rd, Cheang KI, Clore JN, Baillargeon JP, 
Nestler JE. Total and high-molecular weight adiponectin in 
women with the polycystic ovary syndrome. Metabolism 
2011;60:366-72.  
11. Yilmaz M, Bukan N, Demirci H, Ozturk C, Kan E, Ayvaz 
G, et al. Serum resistin and adiponectin levels in women 
with polycystic ovary syndrome. Gynecol Endocrinol 
2009;25:246-52. 
12. Ardawi MS, Rouzi AA. Plasma adiponectin and insulin 
resistance in women with polycystic ovary syndrome. Fertil 
Steril 2005;83:1708-16.  
13. Sharifi F, Hajihosseini R, Mazloomi S, Amirmogaddami H, 
Nazem H. Decreased adiponectin levels in polycystic ovary 
syndrome, independent of body mass index. Metab Syndr 
Relat Disord 2010;8:47-52.  
14. Spranger J, Mohlig M, Wegewitz U, Ristow M, Pfeiffer AF, 
Schill T, et al. Adiponectin is independently associated with 
insulin sensitivity in women with polycystic ovary syndrome. 
Clin Endocrinol (Oxf) 2004;61:738-46.  
15. Panidis D, Kourtis A, Farmakiotis D, Mouslech T, Rousso 
D, Koliakos G. Serum adiponectin levels in women with 
polycystic ovary syndrome. Hum Reprod 2003;18:1790-6.  
16. Olszanecka-Glinianowicz M, Kuglin D, Dabkowska-Huc A, 
Skalba P. Serum adiponectin and resistin in relation to insulin 
consider body fat composition. Body fat distribution indicators 
such as visceral fat ratio and waist hip ratio are also confounding 
variables in the relationship of adiponectin to insulin resistance in 
PCOS. Moreover, ours being a cross-sectional study, we could not 
distinguish whether adiponectin was a cause or a consequence of 
PCOS pathogenesis. 
In conclusion, lower adiponectin level in the PCOS group was 
observed and adiponectin was associated with lipid metabolism 
and obesity both, which, in turn, is related to insulin resistance in 
PCOS. Further studies are needed to clarify the mechanism of 
adiponectin in PCOS.
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